Adamis Pharmaceuticals Corporation (ADMP) Rating Reiterated by B. Riley
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)‘s stock had its “buy” rating restated by research analysts at B. Riley in a note issued to investors on Wednesday. They presently have a $9.50 price objective on the specialty pharmaceutical company’s stock. B. Riley’s price objective would suggest a potential upside of 83.57% from the company’s previous close.
Other research analysts also recently issued research reports about the stock. ValuEngine downgraded shares of Adamis Pharmaceuticals Corporation from a “hold” rating to a “sell” rating in a research report on Tuesday. Maxim Group reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Adamis Pharmaceuticals Corporation in a research note on Monday, June 12th. Finally, Raymond James Financial, Inc. started coverage on shares of Adamis Pharmaceuticals Corporation in a research report on Tuesday, September 12th. They set an “outperform” rating and a $7.00 price objective for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $8.38.
Shares of Adamis Pharmaceuticals Corporation (ADMP) traded up 1.45% during mid-day trading on Wednesday, reaching $5.25. The company had a trading volume of 126,389 shares. Adamis Pharmaceuticals Corporation has a one year low of $2.40 and a one year high of $6.45. The stock has a 50 day moving average of $5.21 and a 200-day moving average of $4.65. The firm’s market capitalization is $164.59 million.
WARNING: This piece of content was reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/04/adamis-pharmaceuticals-corporation-admp-receives-new-coverage-from-analysts-at-b-riley.html.
Institutional investors have recently made changes to their positions in the stock. First Allied Advisory Services Inc. bought a new stake in shares of Adamis Pharmaceuticals Corporation during the 2nd quarter valued at about $114,000. Stonebridge Capital Advisors LLC increased its holdings in Adamis Pharmaceuticals Corporation by 22.2% in the second quarter. Stonebridge Capital Advisors LLC now owns 27,500 shares of the specialty pharmaceutical company’s stock worth $143,000 after purchasing an additional 5,000 shares in the last quarter. Wells Fargo & Company MN bought a new stake in Adamis Pharmaceuticals Corporation in the second quarter worth approximately $169,000. IFP Advisors Inc increased its holdings in Adamis Pharmaceuticals Corporation by 2,245.6% in the second quarter. IFP Advisors Inc now owns 34,433 shares of the specialty pharmaceutical company’s stock worth $179,000 after purchasing an additional 32,965 shares in the last quarter. Finally, Virtu KCG Holdings LLC increased its holdings in Adamis Pharmaceuticals Corporation by 103.2% in the second quarter. Virtu KCG Holdings LLC now owns 38,474 shares of the specialty pharmaceutical company’s stock worth $200,000 after purchasing an additional 19,538 shares in the last quarter. Institutional investors own 10.14% of the company’s stock.
About Adamis Pharmaceuticals Corporation
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).
Receive News & Ratings for Adamis Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corporation and related companies with MarketBeat.com's FREE daily email newsletter.